PYY and obesity due to melanocortin 4 receptor deficiency: Analogues of GLP-1 are used therapeutically for treatment of diabetes and obesity (Nauck et al., 2021), while treatment with PYY analogues as well as combination treatment with GLP-1 and PYY analogues have been evaluated in ongoing clinical trials (Müller et al., 2022).